Sugi Predict

Sugi Predict / Compounds / SCHEMBL17119666

SCHEMBL17119666

SCHEMBL17119666

CC(C)c1cc2cnc(Cl)cc2n(-c2ccccc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 5/20 0.51
▸ LYN P07948 3/20 0.51
▸ SRC P12931 3/20 0.51
▸ MAT2A P31153 5/20 0.37
▸ BRD4 O60885 2/20 0.36
▸ PIK3CD O00329 2/20 0.35
▸ PIK3R1 P27986 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ PRMT5 O14744 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17119663 0.79 BTK (0.48) BTKLYNSRCCYP1A2CYP3A4
SCHEMBL17120948 0.78 SRC (0.45) BTKLYNSRCBRD4HTT
SCHEMBL17119638 0.74 BTK (0.67) BTKLYNSRC
SCHEMBL501865 0.73 PLA2G7 (0.41) BTKLYNSRCMAT2ABRD4
SCHEMBL17119643 0.72 BTK (0.52) BTKLYNSRCALDH1A1
SCHEMBL17119700 0.72 BTK (0.46) BTKLYNSRCMAT2ABRD4
SCHEMBL22056709 0.71 MAPK1 (0.54) MAT2AALDH1A1LMNAHTTHSD17B10
SCHEMBL17119649 0.71 BTK (0.53) BTKLYNSRCMAT2A
SCHEMBL4426075 0.70 BTK (0.46) BTKLYNSRCMAT2ABRD4
SCHEMBL17119698 0.70 BTK (0.61) BTKLYNSRCALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 BTK 245/4885LYN 330/4885SRC 161/4885
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 BTK 245/4885LYN 330/4885SRC 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.